Reduced mismatch negativity predates the onset of psychosis

Shaikh, Madiha; Valmaggia, Lucia; Broome, Matthew R.; Dutt, Aparna; Lappin, Julia; Day, Fern; Woolley, James B.; Tabraham, Paul; Walshe, Muriel; Johns, Louise; Fusar‐Poli, Paolo; Howes, Oliver; Murray, Robin M.; McGuire, Philip; Bramon, Elvira

doi:10.1016/j.schres.2011.09.022

Cited by 125 publications

(121 citation statements)

References 64 publications

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…Perez et al (21) extended these findings to show that MMN amplitude also "forecasts" the time lag to psychosis onset in CHR individuals; those with more severe MMN abnormalities had shorter times to psychosis. These CHR and related studies (21,(23)(24)(25)(26) draw attention to the importance of identifying early biologic markers of disease vulnerability for predicting the development of psychosis and enhancing individualized risk-estimation/ prevention strategies (20).…”

Section: Forecasting the Development Of Psychosis In High-risk Indivimentioning

confidence: 99%

Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders

Light

Näätänen

2013

Proc. Natl. Acad. Sci. U.S.A.

119

View full text Add to dashboard Cite

Section: Forecasting the Development Of Psychosis In High-risk Indivimentioning

confidence: 99%

Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders

Light

Näätänen

2013

Proc. Natl. Acad. Sci. U.S.A.

119

View full text Add to dashboard Cite

“…Other studies in healthy adolescents have found similar age effects for frequency MMN [110,111], but in older age groups there are consistent reports of MMN amplitude reductions with age [29,59] with maximal amplitudes seen in 20-30 year old adults. Within the UHR literature, age effects have been poorly reported, but some studies have reported adjusted MMN effects assuming a linear relationship between age and MMN amplitude [33, 41,43]. For samples comprising adolescents and young adults, such as the present study, a linear model is adequate.…”

Section: Discussionmentioning

confidence: 92%

“…A power analysis, assuming a moderate effect size (0.5) and a transition rate of 10%, indicates that a sample of at least 35 UHR-T and 346 UHR-NT would be required to reliably detect a difference. Of previous reports, three found significantly reduced MMN in UHR-T compared to UHR-NT [33, 43,44], one found a non-significant difference [45], and one found a difference for duration but not frequency MMN [42]. While the cumulative evidence to date appears to support the notion of reduced MMN in UHR-T, we agree with Bodatsch et al [48] who argue more data are required before a definitive conclusion is drawn, especially with respect to the relative utility of different deviant types as predictors of transition in UHR groups.…”

Section: Discussionmentioning

confidence: 96%

“…However, the relationship between MMN and functional status, especially GAF scores, is a well-replicated finding within schizophrenia [27,112]. Other studies have reported no significant correlation between duration MMN and GAF in UHR [35,39,43,104], but see [34]. The absence of this correlation within the UHR sample challenges the notion of UHR individuals being a homogenous group representative of those in an early stage of psychosis.…”

Section: Discussionmentioning

confidence: 99%

“…During the course of the current longitudinal study, a growing number of reports have either compared MMN in an at-risk group to healthy controls [34][35][36][37][38][39][40][41] or additionally compared UHR individuals who transitioned to psychosis to those who did not transition [33, [42][43][44][45]. Reviews of these studies [9,11,31,46,47] and a meta-analysis [48] have suggested reduced MMN in UHR relative to healthy controls with the majority of studies reporting significant reduction in MMN to at least one type of deviant.…”

Section: Mismatch Negativitymentioning

confidence: 99%

See 2 more Smart Citations

114. Electrophysiological, Cognitive and Clinical Profiles of At-Risk Mental State: The Longitudinal Minds in Transition (MinT) Study

Schall¹,

Fulham²,

Atkinson³

et al. 2017

Biological Psychiatry

View full text Add to dashboard Cite

The onset of schizophrenia is typically preceded by a prodromal period lasting several years during which sub-threshold symptoms may be identified retrospectively. Clinical interviews are currently used to identify individuals who have an ultra-high risk (UHR) of developing a psychotic illness with a view to provision of interventions that prevent, delay or reduce severity of future mental health issues. The utility of bio-markers as an adjunct in the identification of UHR individuals is not yet established. Several event-related potential measures, especially mismatch-negativity (MMN), have been identified as potential biomarkers for schizophrenia. In this 12-month longitudinal study, demographic, clinical and neuropsychological data were acquired from 102 anti-psychotic naive UHR and 61 healthy controls, of whom 80 UHR and 58 controls provided valid EEG data during a passive auditory task at baseline. Despite widespread differences between UHR and controls on demographic, clinical and neuropsychological measures, MMN and P3a did not differ between these groups. Of 67 UHR at the 12-month follow-up, 7 (10%) had transitioned to a psychotic illness. The statistical power to detect differences between those who did or did not transition was limited by the lower than expected transition rate. ERPs did not predict transition, with trends in the opposite direction to that predicted. In exploratory analysis, the strongest predictors of transition were measures of verbal memory and subjective emotional disturbance.

show abstract

Mismatch Negativity in Response to Auditory Deviance and Risk for Future Psychosis in Youth at Clinical High Risk for Psychosis

et al. 2022

View full text Add to dashboard Cite

IMPORTANCEAlthough clinical criteria for identifying youth at risk for psychosis have been validated, they are not sufficiently accurate for predicting outcomes to inform major treatment decisions. The identification of biomarkers may improve outcome prediction among individuals at clinical high risk for psychosis (CHR-P).OBJECTIVE To examine whether mismatch negativity (MMN) event-related potential amplitude, which is deficient in schizophrenia, is reduced in young people with the CHR-P syndrome and associated with outcomes, accounting for effects of antipsychotic medication use.DESIGN, SETTING, AND PARTICIPANTS MMN data were collected as part of the multisite case-control North American Prodrome Longitudinal Study (NAPLS-2) from 8 university-based outpatient research programs. Baseline MMN data were collected from June 2009 through April 2013. Clinical outcomes were assessed throughout 24 months. Participants were individuals with the CHR-P syndrome and healthy controls with MMN data. Participants with the CHR-P syndrome who developed psychosis (ie, converters) were compared with those who did not develop psychosis (ie, nonconverters) who were followed up for 24 months. Analysis took place between December 2019 and December 2021. MAIN OUTCOMES AND MEASURESElectroencephalography was recorded during a passive auditory oddball paradigm. MMN elicited by duration-, pitch-, and duration + pitch double-deviant tones was measured. RESULTSThe CHR-P group (n = 580; mean [SD] age, 19.24 [4.39] years) included 247 female individuals (42.6%) and the healthy control group (n = 241; mean age, 20.33 [4.74] years) included 114 female individuals (47.3%). In the CHR-P group, 450 (77.6%) were not taking antipsychotic medication at baseline. Baseline MMN amplitudes, irrespective of deviant type, were deficient in future CHR-P converters to psychosis (n = 77, unmedicated n = 54) compared with nonconverters (n = 238, unmedicated n = 190) in both the full sample (d = 0.27) and the unmedicated subsample (d = 0.33). In the full sample, baseline medication status interacted with group and deviant type indicating that double-deviant MMN, compared with single deviants, was reduced in unmedicated converters compared with nonconverters (d = 0.43). Further, within the unmedicated subsample, deficits in double-deviant MMN were most strongly associated with earlier conversion to psychosis (hazard ratio, 1.40 [95% CI, 1.03-1.90]; P = .03], which persisted over and above positive symptom severity.CONCLUSIONS AND RELEVANCE This study found that MMN amplitude deficits were sensitive to future psychosis conversion among individuals at risk of CHR-P, particularly those not taking antipsychotic medication at baseline, although associations were modest. While MMN shows limited promise as a biomarker of psychosis onset on its own, it may contribute novel risk information to multivariate prediction algorithms and serve as a translational neurophysiological target for novel treatment development in a subgroup of at-risk individuals.

show abstract

Reduced mismatch negativity predates the onset of psychosis

Cited by 125 publications

References 64 publications

Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders

Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders

114. Electrophysiological, Cognitive and Clinical Profiles of At-Risk Mental State: The Longitudinal Minds in Transition (MinT) Study

Mismatch Negativity in Response to Auditory Deviance and Risk for Future Psychosis in Youth at Clinical High Risk for Psychosis

Contact Info

Product

Resources

About